Clinical Trials Browser

Phase 3 × lenvatinib × 90 days × Clear all

Hematologic Neoplasms

NCT04164199 2026-06-03

Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies

Phase 3 Completed

404 enrolled

Advanced Malignancies

NCT07405164 2026-05-29

MK-6482-043

Phase 3 Recruiting

450 enrolled

Genitourinary

Carcinoma, Renal Cell, von Hippel-Lindau Disease

NCT04246177 2026-05-14

LEAP-012

Phase 3 Completed

479 enrolled

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Hepatocellular

NCT04736706 2026-05-06

MK-6482-012

Phase 3 Active not recruiting

1,653 enrolled

Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT04199104 2026-05-05

A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010)

Phase 3 Completed

511 enrolled 20 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT04586231 2026-05-05

MK-6482-011

Phase 3 Active not recruiting

747 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT07537946 2026-04-17

Local Consolidation After Sintilimab Plus Lenvatinib for Metastatic Liver Cancer

Phase 3 Not yet recruiting

400 enrolled

Gastrointestinal

Carcinoma, Hepatocellular, Neoplasm Metastasis

NCT05301842 2026-04-07

EMERALD-3

Phase 3 Active not recruiting

760 enrolled

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT04039607 2026-04-06

CheckMate 9DW

Phase 3 Active not recruiting

732 enrolled 1 FDA

Gastrointestinal

Carcinoma, Hepatocellular

NCT03517449 2026-03-19

MK-3475-775

Phase 3 Completed

827 enrolled 34 charts 1 FDA

Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Endometrial Neoplasms

NCT07475026 2026-03-16

A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence

Phase 3 Not yet recruiting

198 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT05523323 2026-03-13

A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010/LEAP-010)-China Extension

Phase 3 Completed

112 enrolled 16 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck

Clinical Trials

MK-3475-587

Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies

MK-6482-043

LEAP-012

MK-6482-012

A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010)

MK-6482-011

Local Consolidation After Sintilimab Plus Lenvatinib for Metastatic Liver Cancer

EMERALD-3

CheckMate 9DW

MK-3475-775

A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence

A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010/LEAP-010)-China Extension